Novel players in β-thalassemia dyserythropoiesis and new therapeutic strategies

Current Opinion in Hematology

Volumn 23, Issue 3, 2016, Pages 181-188

  Arlet, Jean Benoît ^a,b,c,d   Dussiot, Michaël ^a,b,c   Moura, Ivan C ^a,c,d   Hermine, Olivier ^a,c,d   Courtois, Geneviève ^a,c,d  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c PARIS DESCARTES SORBONNE PARIS CITÉ UNIVERSITY   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Dyserythropoiesis; Growth differentiation factor 11; Heat shock protein 70; Hepcidin; Thalassemia

Indexed keywords

ACE 056; ACTIVIN RECEPTOR; CHAPERONE; ERYTHROPOIETIN; FAS ANTIGEN; FAS LIGAND; GROWTH DIFFERENTIATION FACTOR; GROWTH DIFFERENTIATION FACTOR 11; HEAT SHOCK PROTEIN 70; HEMOGLOBIN ALPHA CHAIN; HEPCIDIN; IRON; JANUS KINASE 2; RECEPTOR BLOCKING AGENT; SOTATERCEPT; TRANSCRIPTION FACTOR GATA 1; TRANSFERRIN; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANEMIA; APOPTOSIS; BASOPHIL; BETA THALASSEMIA; CELL EXPANSION; CELL MATURATION; CYTOPLASM; DYSERYTHROPOIESIS; ENZYME ACTIVATION; ERYTHROBLAST; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; HUMAN; IRON TRANSPORT; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; REVIEW; STEM CELL EXPANSION; UPREGULATION; ANIMAL; BETA-THALASSEMIA; ERYTHROPOIESIS; METABOLISM;

ANIMALS; BETA-THALASSEMIA; ERYTHROPOIESIS; HUMANS;

EID: 84954492040     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000231     Document Type: Review

References (27)

1. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001; 2:245-255.
2. Khandros E, Weiss MJ. Protein quality control during erythropoiesis and hemoglobin synthesis. Hematol Oncol Clin North Am 2010; 24:1071-1088.
3. Ginzburg Y, Rivella S. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011; 118:4321-4330.
4. Kautz L, Jung D, Du S, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood 2015; 126:2031-2037.
5. Liu Y, Pop R, Sadegh C, et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 2006; 108:123-133.
6. Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med 2013; 19:437-445.
7. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med 2014; 20:398-407.
8. Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood 1993; 82:374-377.
9. Mathias LA, Fisher TC, Zeng L, et al. Ineffective erythropoiesis in betathalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol 2000; 28:1343-1353.
10. Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000; 96:3624-3629.
11. Arlet JB, Ribeil JA, Guillem F, et al. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia. Nature 2014; 514:242-246.
12. Rivella S. β-Thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica 2015; 100:418-430.
13. Wickramasinghe SN, Bush V. Observations on the ultrastructure of erythropoietic cells and reticulum cells in the bone marrow of patients with homozygous beta-thalassaemia. Br J Haematol 1975; 30:395-399.
14. Finotti A, Breda L, Lederer CW, et al. Recent trends in the gene therapy of β-thalassemia. J Blood Med 2015; 6:69-85.
15. Ginzburg Y, Rivella S. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011; 118:4321-4330.
16. Ribeil JA, Arlet JB, Dussiot M, et al. Ineffective erythropoiesis in β-thalassemia. Scientific World Journal 2013; 2013:394295.
17. Cazzola M, Guarnone R, Cerani P, et al. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91:2139-2145.
18. Chen JS, Lin KH, Wang St, et al. Blunted serum erythropoietin response to anemia in patients polytransfused for β-thalassemia major. J Pediatr Hematol Oncol 1998; 20:140-144.
19. Libani IV, Guy EC, Melchiori L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood 2008; 112:875-885.
20. De Maria Testa U, Luchetti L, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999; 93:796-803.
21. Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood 2014; 123:3864-3872.
22. Suragani RN, Cadena SN, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 2014; 20:408-414.
23. Ribeil JA, Zermati Y, Vandekerckhove J, et al. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 2007; 445:102-105.
24. Kihm AJ, Kong Y, Hong W, et al. An abundant erythroid protein that stabilizes free alpha-haemoglobin. Nature 2002; 417:758-763.
25. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest 2013; 123:1531-1541.
26. Casu C, Aghajan M, Oikonomidou PR, et al. Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica 2016; 101:e8-e11.
27. Negre O, Bartholomae C, Beuzard Y, et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease. Curr Gene Ther 2015; 15:64-81.